Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

MLA

Weisel, K., et al. Carfilzomib and Dexamethasone versus Eight Cycles of Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma : An Indirect Comparison Using Data from the Phase 3 ENDEAVOR and CASTOR Trials. Jan. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f8b56d60dc9d61acc8839745cee8927f&authtype=sso&custid=ns315887.

APA

Weisel, K., Majer, I., DeCosta, L., Oriol, A., Goldschmidt, H., Ludwig, H., Campioni, M., Szabo, Z., Dimopoulos, M., & Universitat Autònoma de Barcelona. (2020). Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma : an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials.

Chicago

Weisel, K., I. Majer, L. DeCosta, Albert Oriol, H. Goldschmidt, H. Ludwig, M. Campioni, Z. Szabo, Meletios Dimopoulos, and Universitat Autònoma de Barcelona. 2020. “Carfilzomib and Dexamethasone versus Eight Cycles of Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma : An Indirect Comparison Using Data from the Phase 3 ENDEAVOR and CASTOR Trials,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f8b56d60dc9d61acc8839745cee8927f&authtype=sso&custid=ns315887.